ADIA Nutrition Proudly Launches Adia Labs LLC and Begins Sales of Branded Stem Cell Products

Rhea-AI Summary

ADIA Nutrition (OTC Pink: ADIA) has launched Adia Labs , a new division focused on regenerative medicine. The company introduces two key products: AdiaVita, a private-label umbilical cord stem cell product guaranteeing 100 million viable cells and 3 trillion exosomes per unit, and AdiaLink, an upcoming product offering 3.5 trillion exosomes per unit.

The launch was enabled through a partnership with an FDA-approved laboratory, allowing ADIA to offer these products under its own brand. The products are specifically designed for clinical research, studies, and trials, targeting a potential client base of over one million doctors and clinics nationwide.

These products aim to address various conditions, including autoimmune diseases, degenerative disorders, and injury recovery, focusing on non-invasive biological treatments. Doctors and clinics can purchase these products through adialabs.com.

Positive

• Partnership with FDA-approved laboratory secured
• Large potential market of over 1 million doctors/clinics
• Launch of new revenue stream through stem cell products
• Product differentiation with guaranteed cell/exosome counts

Negative

• None.

Winter Park, Florida--(Newsfile Corp. - February 20, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a trailblazer in healthcare and supplementation, proudly announces the launch of Adia Labs LLC, a new division dedicated to advancing regenerative medicine. This initiative underscores ADIA Nutrition's commitment to providing high-quality products for the research and medical community.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/240585_img_5218.jpg

Introducing Adia Labs LLC: Adia Labs focuses on delivering premium regenerative medicine solutions, specifically tailored for clinical research, studies, and trials. The division introduces:

• AdiaVita: A private-label product featuring umbilical cord stem cells. Each unit of AdiaVita guarantees a minimum of 100 million viable cells and 3 trillion exosomes, designed to support advanced medical research and therapeutic applications. This product has undergone rigorous third-party verification to ensure unparalleled quality, purity, and potency.
• AdiaLink: Coming soon, this product will offer exosomes with a guaranteed count of 3.5 trillion per unit. It's specifically crafted for exclusive use in clinical studies, trials, and research by doctors and clinics, aiming to push the boundaries of medical science.

The establishment of Adia Labs was made possible through a groundbreaking deal with an esteemed FDA-approved laboratory. This partnership allows ADIA Nutrition to offer AdiaVita under its own brand, ensuring that the products meet the highest standards of efficacy and safety. This collaboration leverages the lab's expertise in stem cell technology, reinforcing ADIA Nutrition's mission to provide cutting-edge, quality-driven health solutions.

Larry Powalisz, CEO of ADIA Nutrition, stated, "Our expansion into regenerative medicine is more than just growth; it's a step towards redefining healthcare. With Adia Med and now Adia Labs, we are dedicated to advancing medical science while maintaining the highest standards of quality and safety. Through our research, we estimate that we have over one million doctors and/or clinics as our potential client base."

Adia Labs is set to meet the growing demand for non-invasive, biological treatments for various conditions, including autoimmune diseases, degenerative disorders, and recovery from injuries. With its unique composition, Adia Labs aims to offer an accessible and effective solution for those seeking the benefits of stem cell therapy.

Doctors and clinics nationwide can now purchase these umbilical cord stem cell and exosome products for research, trials, and studies from Adia Labs. For pricing and further information, they should visit adialabs.com.

With stem cells, Adia Med opens new avenues for repairing and regenerating damaged tissues, providing hope for various health conditions such as autoimmune or cognitive diseases.

This launch not only expands ADIA Nutrition's product line but also positions them at the forefront of regenerative medicine, promoting a future where innovative treatments are more accessible and effective.

For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.

About ADIA Nutrition Inc.:

Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com

Website: www.adiamed.com

Website: www.adialabs.com

Website: www.biolete.com

Website: www.cementfactory.co

Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240585

FAQ

What products has ADIA Nutrition launched through Adia Labs in February 2025?

ADIA Nutrition launched AdiaVita, a umbilical cord stem cell product with 100 million viable cells and 3 trillion exosomes, and announced AdiaLink, an upcoming product with 3.5 trillion exosomes per unit.

How many potential clients does ADIA estimate for their new stem cell products?

ADIA estimates a potential client base of over one million doctors and/or clinics for their stem cell products.

What medical conditions will ADIA's new stem cell products target?

ADIA's stem cell products target autoimmune diseases, degenerative disorders, and injury recovery through non-invasive biological treatments.

What are the key specifications of ADIA's AdiaVita stem cell product?

AdiaVita guarantees a minimum of 100 million viable cells and 3 trillion exosomes per unit, and has undergone third-party verification for quality, purity, and potency.

Where can medical professionals purchase ADIA's new stem cell products?

Doctors and clinics can purchase ADIA's umbilical cord stem cell and exosome products through adialabs.com.